drugset
drugset / Trial / NCT05642403

A Study of XW001 in Healthy Adult Subjects

NCT05642403 ↗

Phase 1 Completed 81 enrolled Hangzhou Sciwind Biosciences Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

This is the first-in-human, single-center, randomized, double-blinded, placebocontrolled, single-dose and multiple-dose escalation Phase Ia study

Timeline

Start
2021-01-03
Primary completion
2022-06-20
Completion
2022-06-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator XW001 Unknown — Inhaled

Indications

respiratory syncytial virus infectious disease